New York State Common Retirement Fund’s Crinetics Pharmaceuticals CRNX Stock Holding History

New York State Common Retirement Fund’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.14M	Sell	141,618 -4,505	-3%	-$201K	0.01%	1009
2025 Q4	$6.8M	Sell	146,123 -2,154	-1%	-$95.9K	0.01%	908
2025 Q3	$6.18M	Buy	148,277 +7,359	+5%	+$235K	0.01%	969
2025 Q2	$4.05M	Buy	140,918 +3,000	+2%	+$92.6K	0.01%	1146
2025 Q1	$4.63M	Sell	137,918 -17,508	-11%	-$654K	0.01%	1088
2024 Q4	$7.95M	Buy	155,426 +7,735	+5%	+$433K	0.01%	896
2024 Q3	$7.55M	Sell	147,691 -19,051	-11%	-$983K	0.01%	922
2024 Q2	$7.47M	Buy	166,742 +14,250	+9%	+$658K	0.01%	945
2024 Q1	$7.14M	Buy	152,492 +124,767	+450%	+$4.88M	0.01%	962
2023 Q4	$986K	Buy	27,725 +44	+0.2%	+$1.35K	﹤0.01%	1802
2023 Q3	$823K	Buy	27,681 +4,942	+22%	+$102K	﹤0.01%	1844
2023 Q2	$410K	Sell	22,739 -6,025	-21%	-$120K	﹤0.01%	2182
2023 Q1	$462K	Sell	28,764 -10,356	-26%	-$192K	﹤0.01%	2218
2022 Q4	$716K	Sell	39,120 -28	-0.1%	-$493	﹤0.01%	2142
2022 Q3	$769K	Buy	39,148 +5,156	+15%	+$105K	﹤0.01%	2098
2022 Q2	$634K	Buy	33,992 +2,571	+8%	+$51.3K	﹤0.01%	2239
2022 Q1	$690K	Buy	31,421 +5,104	+19%	+$103K	﹤0.01%	2265
2021 Q4	$748K	Sell	26,317 -70	-0.3%	-$1.73K	﹤0.01%	2224
2021 Q3	$555K	Sell	26,387 -5,135	-16%	-$107K	﹤0.01%	2404
2021 Q2	$594K	Buy	31,522 +6,722	+27%	+$118K	﹤0.01%	2502
2021 Q1	$379K	Hold	24,800	–	–	﹤0.01%	2567
2020 Q4	$350K	Hold	24,800	–	–	﹤0.01%	2518
2020 Q3	$389K	Hold	24,800	–	–	﹤0.01%	2336
2020 Q2	$434K	Buy	24,800 +12,100	+95%	+$206K	﹤0.01%	2290
2020 Q1	$187K	Hold	12,700	–	–	﹤0.01%	2490
2019 Q4	$319K	Hold	12,700	–	–	﹤0.01%	2515
2019 Q3	$191K	Hold	12,700	–	–	﹤0.01%	2794
2019 Q2	$318K	Buy	12,700 +8,600	+210%	+$213K	﹤0.01%	2594
2019 Q1	$93K	Hold	4,100	–	–	﹤0.01%	2970
2018 Q4	$123K	Buy	+4,100	New	+$115K	﹤0.01%	2902

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

New York State Common Retirement Fund's CRNX Position: Q1 2026 in Review

New York State Common Retirement Fund reduced its Crinetics Pharmaceuticals (CRNX) stake by 3.1% in Q1 2026, selling an estimated $201K and leaving 141,618 shares worth $5.14M. The position accounts for 0.01% of the portfolio, ranked #1009.

New York State Common Retirement Fund first reported a position in CRNX in Q4 2018 and has held it in 30 quarters since. The position peaked at $7.95M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

New York State Common Retirement Fund held 141,618 shares of Crinetics Pharmaceuticals worth $5.14M as of Q1 2026.
New York State Common Retirement Fund sold 4,505 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $201K.
Crinetics Pharmaceuticals made up 0.01% of New York State Common Retirement Fund's portfolio in Q1 2026, its #1009 holding.
New York State Common Retirement Fund first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
New York State Common Retirement Fund's Crinetics Pharmaceuticals position peaked at $7.95M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on New York State Common Retirement Fund's 13F filing for Q1 2026, filed 6 May 2026.